Updated on 4 January 2013
US FDA nod for rizatriptan benzoate
Glenmark Generics, the US subsidiary of Glenmark Pharmaceuticals, has received the US Food and Drug Administration's final approval for rizatriptan benzoate tablets, its generic version
of Merck's Maxalt tablets. The company has commenced shipping immediately upon approval.
The approval is for the 5 mg and 10 mg of rizatriptan. According to IMS Health for the 12 month period ending September 2012, rizatriptan benzoate tablets achieved sales of $333 million. Glenmark's current portfolio consists of 82 products authorized for distribution in the US marketplace, and 46 ANDAs are pending approval with the US FDA.
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
